AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02188888 — intervention group
Intervention type: DRUG
Intervention: esmolol
Description: Strict heart rate control: esmolol at any dose to maintain heart rate between 95 and 80 bpm
Study NCT02925299 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FlorenceM (US) and FlorenceX (UK)
Description: The automated closed loop system (FlorenceM in US) will consist of:~Next generation sensor augmented Medtronic insulin pump 640G (Medtronic Minimed, CA, USA) incorporating the Medtronic Guardian3 CGM and glucose suspend feature.~The automated closed loop system (FlorenceX in UK) will consist of:~The DANA Diabecare R insulin pump (Sooil Development, Korea) incorporating the Dexcom G6 CGM.~An Android smartphone containing the Cambridge model predictive algorithm and communicating wirelessly with the insulin pump using a proprietary translator device.
Study NCT02925299 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insulin pump therapy
Description: Subjects will continue using their own insulin pump for 6 months.
Study NCT03313167 — intervention group
Intervention type: OTHER
Intervention: Non-interventional
Description: Non-interventional
Study NCT03414931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NMDA
Description: Use of an NMDA enhancer for the treatment of MDD in late life
Study NCT03414931 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: Use of SSRI as an active comparator
Study NCT03414931 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Cap
Description: Use of placebo as a comparator
Study NCT02213861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHAPE
Description: topical gel
Study NCT03367637 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard palliative care
Description: Standard care includes regular follow-up phone calls and home visits by the RPCHO staff for all advanced cancer patients at RPCHO, though the timing of these calls is variable and is selected by the discretion of the team. In addition, patients can contact providers on a landline number available during business hours and staffed by an on-call palliative care provider as and when needed. For after-hours emergency assistance, patients have the option of contacting the on-call palliative-care physicians for assistance.
Study NCT03367637 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smart Phone based symptom evaluation application
Description: In addition to the standard palliative care currently provided at the RPCHO, patients will receive biweekly reminders to fill out the African Palliative Care Outcomes Scale (APCA POS) on the new smartphone application on their phones. It is a short symptom assessment questionnaire with responses on 5-point severity scale. In addition to bi-weekly frequency, patients can complete the symptom assessment at any time they feel their symptoms are poorly controlled. The team at RPCHO will be able to track all enrolled patients on a desktop dashboard. Any score of 2 or higher will be flagged. The providers at RPCHO will respond to such patients during business hours via call or text and will advise the patients as indicated or triage to a fellow team member.
Study NCT04145232 — intervention group
Intervention type: BIOLOGICAL
Intervention: Collection of biopsy (FFPE), blood (PBMC) and stool
Description: Patients receiving routine treatment (immunotherapy using anti-PD1 / anti-PDL1 and / or anti CTLA4 antibodies), financed by the Polish National Health Fund (NFZ).
Study NCT00492128 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan/amlodipine or losartan/hydrochlorothiazide
Description: Losartan 50mg/amlodipine 5mg and the fixed dose combination drug of losartan 50mg/hydrochlorothiazide 12.5mg once a day during 12 months.
Study NCT00492128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan/amlodipine or losartan/hydrochlorothiazide
Description: Losartan 50mg/amlodipine 5mg and the fixed dose combination drug of losartan 50mg/hydrochlorothiazide 12.5mg once a day during 12 months.
Study NCT01276054 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: technetium Tc 99m sulfur colloid
Description: Given intradermally and periareolarly
Study NCT01276054 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: technetium Tc 99m sulfur colloid
Description: Given intradermally and periareolarly
Study NCT01276054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylene blue
Description: Given subcutaneously
Study NCT01276054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylene blue
Description: Given subcutaneously
Study NCT01276054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: indocyanine green solution
Description: Given subcutaneously
Study NCT01276054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indocyanine green solution
Description: Given subcutaneously
Study NCT01276054 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sentinel lymph node biopsy
Description: Undergo sentinel lymph node biopsy
Study NCT01276054 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sentinel lymph node biopsy
Description: Undergo sentinel lymph node biopsy
Study NCT01276054 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: axillary lymph node biopsy
Description: Undergo axillary lymph node biopsy
Study NCT01276054 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: axillary lymph node biopsy
Description: Undergo axillary lymph node biopsy
Study NCT01276054 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bioimpedance spectroscopy
Description: Correlative studies
Study NCT01276054 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bioimpedance spectroscopy
Description: Correlative studies
Study NCT01276054 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT01276054 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT01276054 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lymphedema management
Description: Undergo axillary reverse mapping
Study NCT00148096 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Mechanical Heat Recovery Ventilation
Description: De-humidification without loss of heat
Study NCT00148096 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical Heat Recovery Ventilation
Description: De-humidification without loss of heat
Study NCT04469335 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mobile neurofeedback
Description: to maximize usability and effectiveness, we would like to conduct a study that regulates theta/beta ratio using mobile app-based Neurofeedback Training Equipment (OmniCNS).~The actual Neurofeedback training allows you to download and use the omnifit brain_Game, an application with an audio guide. After the pre-assessment, the researcher will provide guidance to subjects and carers on how to use the application, and demonstrate how to use it in practice. For 2 weeks, 4 weeks and 6 weeks, phone calls are conducted to check whether they are used or not and for any inconvenience. After 12 weeks of Neurofeedback training, the device is returned and post-evaluated.~The application is equipped with four types of games and is instructed to use the three-day-a-week application. For Neurofeedback attention and cognitive training, use a headset with left and right frontal lobe 2 channel-EEG sensors to perform the game through feedback to see if it is concentrating well.
Study NCT04469335 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham mobile neurofeedback
Description: It uses the sham devices and programs as the Neurofeedback, but it is not usually possible to obtain the expected effects of the Neurofeedback by providing random feedback regardless of actual brain waves.~In case of Sham control group, parental education is conducted the same for each clinical evaluation, and in case of Sham control group, actual Neurofeedback is applied if patients and parents want it after the end of the study.
Study NCT04469335 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: medication + mobile neurofeedback
Description: The mobile needback is applied to patients who are taking methylphenidate or atomoxetine, which is a standard ADHD treatment, but have not been remissioned with more than 4 points of CGI-S.
Study NCT04469335 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: medication + Sham mobile neurofeedback
Description: The sham mobile needback is applied to patients who are taking methylphenidate or atomoxetine, which is a standard ADHD treatment, but have not been remissioned with more than 4 points of CGI-S.
Study NCT01493076 — intervention group
Intervention type: DEVICE
Intervention: Primary cannulation/precut sphincterotomie with the Baby-S
Description: At the papilla the ankle for cannulation was optimized due to changes of the position of the sphincterotome, its lay in the working channel and the tension of the Albaran-lever and the cutting wire. After successful cannulation, the catheter with the sphincterotome inside was slightly pushed into the duct. If necessary, the baby-sphincterotome was replaced with a guide wire and than conventional endoscopic sphincterotomie was completed with a standard traction-type sphincterotome.
Study NCT03465969 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: tacrolimus
Description: oral
Study NCT01637129 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: Transcranial Magnetic Stimulation, repetitive at 1Hz
Study NCT01637129 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Magnetic Stimulation
Description: Sham Magnetic Stimulation
Study NCT03061396 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Matching points PC6+CV12
Description: Choose both Neiguan(PC6) and Zhongwan point(CV12).The needles are connected through a electro-acupuncture apparatus, the positive poles are linked to the needle, and the reference poles are located near the acupoint about 1cm with a electrode.Frequency is 2/10 hertz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10 milliampere. And plus 5-hydroxytryptamine-3 (5-HT3) antagonist (Ramosetron, Tropisetron，Granisetron or Ondansetron) and dexamethasone.
Study NCT03061396 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single points PC6
Description: Choose Neiguan(PC6)of double upper limb.The needles are connected through a electro-acupuncture apparatus, the positive poles are linked to the needle, and the reference poles are located near the acupoint about 1cm with a electrode.Frequency is 2/10 hertz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10 milliampere. And plus 5-hydroxytryptamine-3 (5-HT3) antagonist (Ramosetron, Tropisetron，Granisetron or Ondansetron) and dexamethasone.
Study NCT01867177 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: HIV testing
Description: HIV testing. Enhanced testing protocol is used: RESPECT, an evidence-based HIV prevention counseling intervention helping people increase condom use, decrease risky behaviors (resulting in a decrease in STIs) compared to those who did not receive the intervention. RESPECT includes: one-on-one counseling using a structured protocol; teachable moments during counseling to motivate clients to change risk-taking behaviors; to explore the contexts in which risk behaviors occur to increase awareness of susceptibility; and negotiate achievable next steps with the client that support the larger risk reduction goal. Implemented using a structured protocol with monitoring to ensure the fidelity of the testing intervention.
Study NCT01867177 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard of HIV care
Description: Standard linkage and referral to HIV care includes HIV counseling, testing, and referrals. Both intervention and comparison groups will receive these.
Study NCT01867177 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV care utilization
Description: Sites will use a peer-based, client navigation model of an Integrated HIV/AIDS Early Intervention Services (ARTAS), Community Health Worker (CHW) Program, case management/support services linking people to continuous, coordinated care after HIV dx. Another site will do Motivational Enhancement Intervention (MEI) sessions with quality of ife workshops and support groups. Health Educators recruit clients, make appointments, escort to test sites, intake, review. Additional components can include food security support, social and group support, drop in centers, text messaging and social media, depending on sites. All sites focus on approaches to reach community members and facilitate their supportive linkage to care with behavioral and structural supports.
Study NCT04421703 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Med-South Lifestyle Program
Description: The Med-South Lifestyle Program is an evidence-based behavior change intervention that translates the PREDIMED (Mediterranean) dietary pattern for a Southeastern US population and includes support for increased physical activity.
Study NCT01339572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: 240 mcg/kg/day based on ideal body weight will be given for the following conditions:~1. Pre-apheresis peripheral blood CD34+ count \<20 cells/μL on day 5.~2. Estimated CD34+ cell collection is \< 25% of target cell dose after 1 day of apheresis.~3. Estimated CD34+ cell collection is \< 50% of target cell dose after 2 days of apheresis.
Study NCT01339572 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Filgrastim
Description: All patients will receive filgrastim starting 4 days prior to apheresis (D1-4 mobilization). The dose and schedule of filgrastim will based upon the risk category of the patient:~* Standard risk: 5 μg/kg SQ BID.~* High risk: 10 μg/kg SQ BID.
Study NCT01339572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: All patients will receive filgrastim starting 4 days prior to apheresis (D1-4 mobilization). The dose and schedule of filgrastim will based upon the risk category of the patient:~* Standard risk: 5 μg/kg SQ BID.~* High risk: 10 μg/kg SQ BID.
Study NCT00732537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled Nitric Oxide
Description: iNO started at 20 ppm for 1 hour, then weaned hourly over the next 4 hours (20 ppm to 10 to 5 to 2.5 to 1 to off). If >5% drop in oxygen saturation was observed during weaning, study gas was increased to the previous concentration and weaning done 2 hourly. If > 5% drop in oxygen saturation or >5% Methemoglobin was observed during initial administration, the study gas would be weaned over 30 minutes and the infant would exit. The iNO was introduced into an oxygen hood (Oxydome ™ disposable hood from Maxtex ® Inc.) using an INOvent (Datex-Ohmeda). The INOvent ® was connected to the oxyhood by placing the injector module inline on the dry side of the humidifier chamber. Monitoring of O2, NO2, NO was done by placing the end of the sample line inside the oxyhood. A Masking Shield covered the Display/Control Panel and Cylinder Gauges, in order to maintain masking of the intervention. Only the respiratory therapist and research coordinator was aware of the allocation assignment.
Study NCT00732537 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxygen (>90% by hood) - standard therapy
Description: Oxygen (>90% by hood, standard therapy for PPHN prior to intubation) was introduced into an oxygen hood (Oxydome ™ disposable hood from Maxtex ® Inc.) using an INOvent (Datex-Ohmeda). The INOvent ® was connected to the oxyhood by placing the injector module inline on the dry side of the humidifier chamber. If the baby was randomized to the control group and did not receive NO, the INOmax® cylinder was opened and used only to pressurize the system, which prevented the Low NO Pressure alarm. A Masking Shield covered the Display/Control Panel and Cylinder Gauges, in order to maintain masking of the intervention. Only the respiratory therapist and research coordinator was aware of the allocation assignment.
Study NCT04159753 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Spinal Cord Stimulator
Description: We will record patient's experience on the 30-Day FDA approved Burst Spinal Cord Stimulator Trial (BurstDR™, Abbott Saint Jude Medical).
Study NCT02877771 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: t:slim insulin pump with predictive low glucose suspend
Description: To assess the functionality of a predictive low glucose suspend (PLGS) system that uses Continuous Glucose Monitoring (CGM) values to suspend basal insulin delivery when hypoglycemia is predicted as well as resume basal insulin delivery once Continuous Glucose Monitoring (CGM) values begin to increase.
Study NCT04588467 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical treatment
Description: Pregnant women complaining thrombosed haemorrhoids will receive dietary modification (intake of at lest 3 liers of water), stool-softeners (a 25 ml solution containing: Macrogol 3350: 13.125 g Sodium chloride: 0.3508 g Sodium hydrogen carbonate: 0.1786 g Potassium chloride: 0.0502 g) and local anesthetics application
Study NCT04588467 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Description: Pregnant women complaining thrombosed haemorrhoids will receive local excision or thrombectomy under local anesthesia
Study NCT00948441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25% ethanol
Description: Study Lock -25% Ethanol- The ethanol lock therapy consists of placing up to 2.3 ml of 25% ethanol into the central venous catheter and allowing it to dwell for 4 to 12 hours per day.
Study NCT00948441 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: heparin lock
Description: Placebo Lock - Heparin - These will be prepared in a sterile fashion in the Pharmacy of Children's Hospital of Pittsburgh in 10 day supplies as 1ml lock syringes utilizing 100 units/ml if the central venous catheter is accessed once daily and 10 units/ml if accessed more than once daily. The lock solution will be instilled and allowed to dwell for 4 to 12 hours.
Study NCT02234895 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lateral wedge
Description: This will be a randomized cross-over study where all participants will receive both orthoses over a six month period. Each intervention will last two months, separated by a two month washout period of no orthotics wear, and will be preceded and followed by a laboratory-based gait and pain assessment. Two months has been chosen as the ideal time frame to ensure maximum participant adherence, to observe clinically meaningful changes in symptoms, and to minimize degradation of the insoles.
Study NCT02234895 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lateral wedge plus medial arch support
Description: This will be a randomized cross-over study where all participants will receive both orthoses over a six month period. Each intervention will last two months, separated by a two month washout period of no orthotics wear, and will be preceded and followed by a laboratory-based gait and pain assessment. Two months has been chosen as the ideal time frame to ensure maximum participant adherence, to observe clinically meaningful changes in symptoms, and to minimize degradation of the insoles.
Study NCT00947882 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Mannitol 50 mg/mL solution
Study NCT00947882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix 10 mg
Description: 10 mg degarelix, 40 mg/mL solution
Study NCT00947882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix 20 mg
Description: 20 mg degarelix, 40 mg/mL solution
Study NCT00947882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix 30 mg
Description: 30 mg degarelix, 40 mg/mL solution
Study NCT01947140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pralatrexate
Description: Phase I - Schedule A: Intravenous drug given on days 1 and 8 of each 21 day cycle Schedule B: Intravenous drug given on days 1 and 15 of each 28 day cycle Dose escalation from 10 mg/m2 to 25 mg/m2~Phase II - 25 mg/m2 will be given intravenously once weekly on days 1 and 15 on a 28 day cycle.
Study NCT01947140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: Phase I - Schedule A: Intravenous drug given on days 1 and 8 of each 21 day cycle Schedule B: Intravenous drug given on days 1 and 15 of each 28 day cycle Dose escalation from 12 mg/m2 to 14 mg/m2.~Phase II - 12 mg/m2 will be given intravenously once weekly on days 1 and 15 on a 28 day cycle.
Study NCT01385527 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weekly Internet survey
Description: Parents will complete a weekly online survey about medication use.
Study NCT01385527 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Triamcinolone
Description: Topical triamcinolone to all affected areas once daily
Study NCT01385527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Triamcinolone
Description: Topical triamcinolone to all affected areas once daily
Study NCT00634907 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Pharmacogenetic-based warfarin dosing
Description: Prior to elective joint replacement surgery a blood sample is collected for genetic information(genotyping)which was used for calculating warfarin doses for patients randomized to the cytochrome arm. Outcomes in terms of efficacy, safety, and management of warfarin were compared between this group and the group in which warfarin doses are determined per usual care.~NOTE: Standard of care for elective knee and hip replacement at our institution is to receive post-operative warfarin thromboprophylaxis. Administration of warfarin was not specific to this study, nor was the duration of prophylaxis, however, warfarin dosing was influenced by the study arm as noted above.